KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Moderna (MRNA) Interest & Investment Income (2018 - 2026)

Moderna (MRNA) has disclosed Interest & Investment Income for 9 consecutive years, with $72.0 million as the latest value for Q1 2026.

  • For Q1 2026, Interest & Investment Income fell 20.0% year-over-year to $72.0 million; the TTM value through Mar 2026 reached $296.0 million, down 25.06%, while the annual FY2025 figure was $314.0 million, 26.12% down from the prior year.
  • Interest & Investment Income hit $72.0 million in Q1 2026 for Moderna, up from $70.0 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $120.0 million in Q1 2024 and bottomed at $15.0 million in Q1 2022.
  • Average Interest & Investment Income over 5 years is $84.2 million, with a median of $90.0 million recorded in 2025.
  • Year-over-year, Interest & Investment Income surged 1350.0% in 2022 and then dropped 29.13% in 2025.
  • Moderna's Interest & Investment Income stood at $87.0 million in 2022, then increased by 18.39% to $103.0 million in 2023, then dropped by 11.65% to $91.0 million in 2024, then fell by 23.08% to $70.0 million in 2025, then rose by 2.86% to $72.0 million in 2026.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at $72.0 million, $70.0 million, and $73.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.